Wave Life Sciences Quarterly Cash Flow Statement
NASDAQ: WVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Wave Life Sciences free cash flow
In the quarter ended Jun 30, 2026, Wave Life Sciences generated -$53.6 million of operating cash flow and spent $884,000 on capital expenditures. That left free cash flow of -$54.5 million, a free-cash-flow margin of -2397.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Wave Life Sciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -69.36M | -26.09M | -53.18M | -53.85M | -50.47M | -46.88M | 29.25M | -61.78M | -32.92M | -31.56M | -16.26M | 7.25M |
| Net Income growth (YoY) | — | — | -281.79% | — | — | — | — | -951.90% | — | — | — | — |
| Depreciation & Amortization | 858.00K | 841.00K | 844.00K | 856.00K | 865.00K | 875.00K | 907.00K | 948.00K | 999.00K | 1.04M | 1.08M | 1.20M |
| Stock-Based Compensation | 10.73M | 9.06M | 7.35M | 6.47M | 6.20M | 4.95M | 3.24M | 3.53M | 3.48M | 2.88M | 2.35M | 2.28M |
| Change in Working Capital | -1.43M | -24.43M | 3.46M | -1.08M | -8.62M | -9.69M | -84.50M | 6.28M | -1.59M | 6.09M | -21.77M | -48.27M |
| Operating Cash Flow | -53.58M | -59.55M | -33.78M | -44.67M | -46.01M | -63.04M | -43.65M | -46.48M | -27.47M | -33.43M | -33.24M | -34.46M |
| Capital Expenditures | -884.00K | -438.00K | 1.00K | -248.00K | -306.00K | -165.00K | -86.00K | -383.00K | -52.00K | -417.00K | -356.00K | -198.00K |
| Investing Cash Flow | -123.45M | -438.00K | 1.00K | -248.00K | -306.00K | -165.00K | -86.00K | -383.00K | -52.00K | -417.00K | -356.00K | -198.00K |
| Financing Cash Flow | 330.00K | 2.53M | 439.69M | 32.69M | 11.69M | 4.16M | 34.98M | 203.75M | 653.00K | 14.51M | 93.96M | 1.67M |
| Net Change in Cash | -176.58M | -57.47M | 405.86M | -12.25M | -34.58M | -58.99M | -8.86M | 157.00M | -26.95M | -19.41M | 60.42M | -33.02M |
| Free Cash Flow | -54.47M | -59.99M | -33.77M | -44.91M | -46.32M | -63.20M | -43.73M | -46.86M | -27.52M | -33.85M | -33.59M | -34.66M |
This table shows 12 quarterly periods of Wave Life Sciences's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow WVE's reporting calendar. What is a cash flow statement?